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Abstract
Background: Acute diarrhea and acute gastroenteritis (AD/AGE) are common among children in low- and middle-
income countries (LMIC) and high-income countries (HIC). Supportive therapy including maintaining feeding,
prevention of dehydration, and use of oral rehydration solution (ORS), is the mainstay of treatment in all children.
Several additional treatments aiming to reduce the episode duration have been compared to placebo, but the
differences in effectiveness among them are unknown.
Methods and analysis: We will conduct a systematic review of all randomized controlled trials evaluating the use
of zinc, vitamin A, probiotics, prebiotics, synbiotics, racecadotril, smectite, and fermented and lactose-free milk/
formula for AD/AGE treatment in children. The primary outcomes are diarrhea duration and mortality. Secondary
outcomes are diarrhea lasting 3 or 7 days, stool frequency, treatment failure, hospitalizations, and adverse events.
We will search MEDLINE, Ovid EMBASE, CINAHL, the Cochrane Central Register of Controlled Trials (CENTRAL), and
LILACS through Ovid, as well as grey literature resources. Two reviewers will independently screen titles and
abstracts, review full texts, extract information, and assess the risk of bias (ROB) and the confidence in the estimate
(with the grading of recommendations, assessment, development, and evaluation [GRADE] approach). Results will
be summarized narratively and statistically. Subgroup analysis according to HIC vs. LMIC, age, nutrition status, and
ROB is planned. We will perform a Bayesian network meta-analysis to combine the pooled direct and indirect
treatment effect estimates for each outcome, if adequate data is available.
Discussion: This is the first systematic review and network meta-analysis that aims to determine the relative
effectiveness of pharmacological and nutritional treatments for reducing the duration of AD/AGE in children. The
results will help to reduce the uncertainty of the effectiveness of the interventions, find knowledge gaps, and/or
encourage further research for other therapeutic options.
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Background
Diarrheal diseases remain the third cause of death among
children younger than 5 years of age [1, 2]. Almost all of
these deaths occur in low- and middle-income countries
(LMIC). Although in high-income countries (HIC) the
disease is rarely fatal, it is a leading cause of emergency
department visits and hospitalizations [3].
Acute diarrhea (AD) is defined by the World Health
Organization (WHO) as the passage of three or more
loose or liquid stools per day, for three or more days and
for less than 14 days [4]. On the other hand, the American
Academy of Pediatrics (AAP) defines acute gastroenteritis
(AGE) as the diarrheal disease of rapid onset, with or
without additional symptoms and signs, such as nausea,
vomiting, fever, or abdominal pain [5]. The AAP restricts
this definition to children 1 month to 5 years of age who
live in developed countries and to episodes of less than
10 days of duration [5]. Although AGE and AD are sup-
ported in two different definitions, they are usually related
to the same disease, a gastrointestinal infection caused by
microorganisms such as rotavirus, Salmonella, E. coli, and
Campylobacter, among others [6]. Nevertheless, the pat-
tern of etiology is variable, given that in HIC, the predom-
inant causes are usually viruses, while in LMIC, the
bacterial microorganisms play a more important role.
AGE is the preferred term in HIC, where it is considered
a self-limited disease with some potential of causing
hospitalization for a few days. Meanwhile in LMIC, the
most common name used is AD, and it is more frequently
associated with a prolonged disease with the potential of
causing severe dehydration, malnutrition, and death. These
differences explain why there are different scopes in the
literature in terms of definitions as well as in terms of treat-
ment recommendations. According to the WHO, the main-
stay of AD’s treatment is the prevention of dehydration
with adequate liquids and oral rehydration salts (ORS),
maintenance of oral feeding, and supplementation of zinc
[4]. In HIC, although the ORS and oral feeding mainten-
ance are also the main recommendations, some guidelines
have either recommended additional treatments such as
probiotics, racecadotril, and smectite and/or have discour-
aged the use of zinc [7, 8].
Efforts in LMIC have been made to reduce mortality by
maintaining the oral feeding and increasing the ORS and
zinc use, which could reduce diarrhea and has some nutri-
tional and immunological advantages [9]. Also, supplemen-
tation with vitamin A and micronutrient mixtures have
been tested for improving different outcomes in AD in the
LMIC setting [10]. On the other hand, in HIC, malnutrition
and mortality not being real problems, the efforts have
focused on reducing the days of diarrhea with the pharma-
cological interventions. Furthermore, in addition to the
micronutrients and pharmacological treatments, other
interventions have been used to reduce the duration of the
disease and the rates of hospitalizations, such as fermented
milks (i.e., yogurt, kefir, or kumis) and the lactose-free
formulas [11, 12].
Trials comparing different interventions have been
carried out in both settings. In comparison to placebo, most
of these interventions have been found effective, an evi-
dence that has been synthesized through some systematic
reviews [11, 13–19], while other reviews are still ongoing
[20, 21]. However, differences seem to exist in the effective-
ness of intervention based on the country setting of the
studies. For instance, zinc trials have been mostly con-
ducted in LMIC, where it was shown to be effective against
placebo [13], and zinc is recommended by the WHO [4]
mostly focused on the LMIC, while it is not routinely rec-
ommended in HIC [8]. Meanwhile, the trials using pharma-
cological treatments against placebo have been conducted
in both HIC and LMIC [15].
As a result, to date, although some interventions have
been shown to be effective, it is not clear whether the chil-
dren should be treated equally regardless of the country
setting or the nutrition status, and neither is it clear which
one of the interventions is better than the others. Only
one recent systematic review performed direct and indir-
ect comparisons and found that racecadotril was the best
available option for reducing the diarrhea duration [22].
However, this review having included only three interven-
tions and probiotics, provided limited information about
search strategies, included and excluded studies, and the
risk of bias (ROB) assessment, it did not assess for poten-
tial effect modifiers and the overall confidence in the esti-
mate, and it was published in Spanish.
To date, there is no systematic review and network
meta-analysis (NMA) that has compared all the available
standard treatments for AD/AGE in children. Therefore,
the aim of this project is to assess the effectiveness and
safety of the different treatments, in addition to the oral
rehydration for AD/AGE in children in relation to one an-
other, based on the specific country setting, through direct
and indirect comparisons using a Bayesian approach, in
order to enhance current treatment of the disease.
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Methods and design
This systematic review and NMA protocol has been regis-
tered in the PROSPERO international prospective register
of systematic reviews (CRD42015023778), and it was devel-
oped following the preferred reporting items for systematic
review and meta-analysis protocols (PRISMA-P) guidance
[23]. The final report will comply with the recommenda-
tions of the PRISMA extension statement for reporting of
systematic reviews incorporating network meta-analyses of
health care interventions [24].
Data sources and search strategy
Literature searches will be performed in MEDLINE,
EMBASE, Global Health through the Ovid platform, and
also in CINAHL, LILACS, and the Cochrane Central
Register of Controlled Trials (CENTRAL) using a combin-
ation of controlled and free-text terms with various syno-
nyms for the disease and the interventions. The example of
the search strategy through Ovid MEDLINE is shown in
Appendix A: Table 2. We will use the validated random-
ized controlled trial (RCT) filters created by the McMaster
University Health Information Research Unit for MED-
LINE and EMBASE through the Ovid platform. These fil-
ters provide a good balance between sensitivity and
specificity [25]. In addition, we will use previously validated
and used filters for identifying pediatric articles in MED-
LINE (translated to the other databases through Ovid),
CINAHL, and CENTRAL [26–28].
Search alerts will be set up for monthly notification, and
the search will be repeated before the final manuscript sub-
mission. Search strategies were developed with liaison with
an experienced librarian. No language, publication status,
or date limit will be used.
We will carry out a manual hand search of bibliograph-
ies of identified RCTs and guidelines. Additionally, we will
perform a grey literature search through (1) trial registries
(e.g., clinicaltrials.gov and the WHO International Clinical
Trials Registry Platform Search Portal), (2) conference
proceedings and abstracts, and (3) dissertation databases
(ProQuest Dissertations and Theses database). We will
contact authors of unpublished work to ensure eligibility.
Eligibility criteria
The search for studies will be limited to RCTs assessing the
efficacy, effectiveness, or safety of different interventions for
AD/AGE in children younger than 18 years of age. The
diarrhea episode will have to be proven or presumed to be
caused by an infectious agent, with a duration of less than
14 days. Diarrhea is usually defined as three or more loose
stools in a 24-h period [4, 5].
We will include RCTs and quasi-RCTs that evaluated
single and/or combined interventions at any dose and
presentation of zinc, vitamin A, micronutrients, smectite,
racecadotril, prebiotics, probiotics, synbiotics, fermented
milks, and lactose-free milks and formula. Regarding pro-
biotics, we will search for trials using, but not restricted
to: Lactobacillus or Bifidobacterium strains, Sacharomyces
boulardii, Bacillus clausii or subtilis, Streptococcus ther-
mophylus, and Enterococcus faecium, or mixtures of two
or more probiotics. Regarding the prebiotics, we will
search for trials studying inulin, fructo- and galacto-
oligosaccharides. We will consider a synbiotic when a
pharmacological preparation contains one or more pro-
biotics and one or more prebiotics.
Regarding fermented milks, we will include studies using
preparations based on S. thermophilus or L. delbrueckii
subsp. bulgaricus cultures such as kefir, kumis, and yogurt.
Fermented milks supplemented with probiotics will be also
included. Finally, as to lactose-free milks, we will include
studies evaluating as interventions lactose-free, or diluted
(by at least 50 %) milks or formula, including soy-based
milks.
We will not include studies testing the effectiveness of
antimicrobials for bacterial or parasitic infections because
these treatments are not empirically recommended and are
only prescribed under certain clinical conditions or for a
specific microorganisms’ detection. We will not include
neither studies testing bismuth nor diphenoxylate since
these drugs are not approved for their use in young chil-
dren. Lastly, we will exclude studies comparing alternative
or non-mainstream interventions, given that we are only in-
terested in widely available treatments approved for their
use in children (standard treatments), and such treatments
are out of the scope of our question.
The studies will have to compare any of these interven-
tions; among them are different doses of the same inter-
vention, or with placebo, or no intervention (conventional
treatment with ORS). In order to be included, the study
will have to report the effectiveness of one or more of the
described interventions with at least one of the outcomes
of interest.
Our primary outcomes are mean diarrhea duration
(hours/days) and mortality. The secondary outcomes
include: diarrhea lasting >3 or 7 days, stool frequency,
diarrhea hospitalizations, treatment failure, and ad-
verse events (vomiting, somnolence/lethargy, ileus,
constipation). Table 1 describes the definitions of the
outcomes. We will exclude studies in patients with
cholera, HIV, or with known or thought to have other
causes of diarrhea such as antibiotic-associated, per-
sistent or chronic diarrhea. In case the trials have in-
cluded children with some of the exclusion criteria,
and the authors report the results separately, we will
use the specific results for our population of interest.
Otherwise, we will include the study if we have infor-
mation about the proportion of children with the ex-
clusion criteria, and this is less than 30 % of the total
sample size.
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Study selection
Paris of reviewers (IDF, CMG, CCG, JMS, AMZ, GPG,
JJY, and RA) will perform, independently and in duplicate,
the screening of available titles and abstracts to assess its
eligibility. As a second step, the full-text articles of the po-
tentially eligible studies will be screened to assess their eli-
gibility. We will include studies where both reviewers
agree about their inclusion. In case of disagreement be-
tween the reviewers, a third member (IDF, CMG, or JMS)
of the team will resolve it. Records of excluded articles in
this stage, along with the reason for ineligibility, will be
saved for future reference. Reviewers will refer to the eligi-
bility criteria during the screening process. Eligible article
citations will be saved in the Endnote X7 library. We will
present the PRISMA flow diagram [29], demonstrating
the search and screening process. We will contact authors
of primary studies during data extraction to obtain any
missing information.
Data extraction
The study data will be collected based on a pre-specified in-
struction extraction form in a Microsoft Excel sheet form.
We will extract the following information: study character-
istics (design, year, duration of follow-up, sample size per
arms, setting, and country), patient characteristics (age, in-
patient/outpatient, nutrition status, days of disease, etiology,
and hydration status), intervention details (doses, adminis-
tration forms), and outcome results (number of events,
mean and standard deviation or standard errors per arm) at
the longest duration of follow-up. All reviewers will test the
data extraction form before the review. Eight reviewers
(IDF, CMG, CCG, JMS, AMZ, GPG, JJY, and RA) will per-
form data extraction, working in pairs independently and in
duplicate. If a consensus cannot be reached, a third desig-
nated reviewer will be involved (IDF, CMG, or JMS).
Assessment of risk of bias in included studies
We will assess all included studies for their ROB. For this
purpose, two independent pairs (IDF, CMG, CCG, JMS,
AMZ, GPG, JJY, and RA) will use a modified version of the
Cochrane ROB tool [30] based on sequence generation, al-
location concealment, blinding of participants, personnel
and outcome assessors, completeness of follow-up, selective
outcome reporting, and other biases. Each criterion will be
assigned a score of “definitely low risk”, “probably low risk”,
“probably high risk”, or “definitely high risk” [31]. We will
try to resolve by consensus the disagreements between two
reviewers when assessing the studies. Nevertheless, if a con-
sensus cannot be reached, a third designated reviewer (IDF
or GHG) from the team will be involved to resolve it.
Direct comparisons and assessment of heterogeneity
We will first describe the results narratively and, where pos-
sible, the direct evidence will be pooled. Given that we ex-
pect clinical and methodological heterogeneity among the
studies (see below in the Rating the confidence in estimates
of the effect in NMA section), which in turn will create
statistical heterogeneity, we will pool direct evidence for
each treatment comparison using a random-effects (RE)
model. In comparison to a fixed-effect model (FE), the RE
model is conservative in that it considers both within- and
among-study variability. The RE models assume that the
observed treatment effect for a study is a combination of a
treatment effect common to all studies plus a component
specific to that study alone [32]. We will pool the outcome
data using a Bayesian RE model [33]. Effect estimates along
with 95 % credible intervals (CrIs) will be estimated using
odds ratio (OR) for binary outcomes, and mean difference
for continuous outcomes, if they are reported using the
same metrics or standardized mean difference (SMD)
otherwise. For studies with binary outcomes, we will add
0.5 to each cell if one arm is zero, whereas we will exclude
studies from the analyses with zero events in both arms.
We will use non-informative priors for all model parame-
ters apart from the heterogeneity variance parameter, for
which we will use the informative prior suggested by
Turner et al. [34] and Rhodes et al. [35]. All Bayesian ana-
lyses will be performed using the Markov Chain Monte
Carlo method.
We will assess heterogeneity by estimating the magnitude
of the between-study variance using the empirical distribu-
tion as estimated by Turner et al. [34] and Rhodes et al.
Table 1 Outcome measures








Duration in hours/days MD (95%CrI)
Mortality Number of deaths OR (95%CrI)
Secondary
Diarrhea lasting
>3 or 7 days
Number of children with













Treatment failure Number of children with
treatment failure
OR (95%CrI)






MD mean difference, OR odds ratio, 95%CrI 95 % credibility interval
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[35], and by using the I2 statistic to quantify the percentage
of variability that is due to true differences between studies
rather than sampling error [36, 37]. We will interpret the I2
using the thresholds set forth by the Cochrane Collabor-
ation [30], and it will be used as a criterion for pooling the
results and for performing additional subgroups analysis. In
case there is important heterogeneity, we will use meta-
regression to explain it if we have enough data to do so.
Otherwise, we will perform subgroup analyses.
We are proposing six a priori hypotheses to explain vari-
ability between studies, therefore, as possible effect modi-
fiers; studies in children [1] in HIC could show a smaller
effect of micronutrients in comparison to LMIC [2]; micro-
nutrient deficiencies or malnutrition could show a smaller
effect of micronutrients in comparison to well-nourished
children [3]; a rotavirus infection could have larger effects
than those that do not specify the etiology [4]; inpatients
could show more larger effects that in outpatients [5]; trials
with a higher ROB could show larger effects than trials with
a lower ROB; and [6] studies with majority of children
younger than 6 months or above 5 years of age could show
a smaller effect, mostly of micronutrients, zinc, or vitamin
A, but also of the rest of the interventions. We will perform
meta-regression using these hypotheses as the study level
covariates, and we will perform a sensitivity analysis based
on the studies with high a ROB.
The differences among the studies related to the country
setting and the nutrition status are closely related. The pre-
viously described differences in the burden of the disease in
children of LMIC in comparison with children of HIC are
related to the higher prevalence of malnutrition and micro-
nutrient deficiencies among the former than the latter.
Thus, zinc, vitamin A, and other micronutrients, and also
essential nutrients are expected to have a higher effect on
reducing the diarrhea in malnourished children than in
eutrophic children. However, the lack of information re-
garding the baseline nutritional or micronutrient status of
the children in the studies is a potential problem; therefore,
the country setting is an approximation to this source of
heterogeneity. We will analyse differences based on both
nutritional/micronutrient status and country setting if we
have enough data to do so. We will interpret the re-
sults of the heterogeneity in the context of the grad-
ing of recommendations, assessment, development,
and evaluation (GRADE) approach [38].
Assessment of reporting bias
We will construct a funnel plot for each outcome to assess
the potential publication bias [39], if we retrieve at least
ten studies [30]. Visual inspection to determine the funnel
asymmetry will be used for this purpose. We will also per-
form the Begg’s rank correlation [40] and Egger’s regres-
sion tests [41] if a similar number of studies is available.
The network meta-analysis: the direct and the indirect
evidence
We will perform a random-effects NMA, as we expect
between-study heterogeneity. Given that many of the treat-
ment combinations available to treat AD/AGE have not
been compared in head-to-head studies, we expect that
some of the possible comparisons between the interven-
tions will not have direct evidence. In the absence of direct
evidence for a given comparison, the indirect comparison
will provide the estimate. In the presence of direct evidence,
the NMA will provide a combined estimate (i.e., direct and
indirect evidence) [42]. We will combine direct and indirect
estimates in a NMA for all interventions on the outcomes
if the assumptions of between-study homogeneity and
transitivity across treatment comparisons are judged to be
justifiable. Violation of the transitivity assumption will
cause inconsistency between direct and indirect estimates
(loop inconsistency) and/or inconsistency between studies
that inform the same treatment comparison but include a
different number of treatment arms (design inconsist-
ency). We will apply the design-by-treatment interaction
model to evaluate both design and loop inconsistency, and
if this suggests inconsistency, then we will apply the loop-
specific method to assess local inconsistency [43–45]. We
will perform a network meta-regression or subgroup ana-
lysis using the same potential treatment effect modifiers
described in the “Direct comparisons and assessment of
heterogeneity” section to explore important heterogeneity
and/or inconsistency. We will also perform a sensitivity
analysis for different heterogeneity priors to assess the ro-
bustness of results [33, 34, 35].
The network geometry and the results in probability
statements as well as forest plots will be presented; this will
ensure interpretability of the results. Effect estimates will be
presented along with their corresponding 95 % CrIs. We
will rank the probabilities with its 95 % CrIs as well as the
surface under the cumulative ranking curve (SUCRA)
values and rankograms [46]. It is expected that the best
treatments will have high SUCRA values while the worst
will have low values. For each paired comparison, we will
present the direct, indirect, or network estimates.
We will fit a Bayesian hierarchical model with non-
informative priors adjusting for correlation of multi-arm
trials, assuming a common-within network heterogeneity
variance. A series of 100,000 burn-in simulations will be
used to allow convergence and then a further 20,000 simu-
lations to produce the outputs. We will assess model con-
vergence on the basis of the Gelman and Rubin diagnostic
test [47]. The analysis will be performed in OpenBUGs
(version 3.2.3) [48].
Rating the confidence in estimates of the effect in NMA
Reviewers (IDF, CMG, CCG, JMS, AMZ, GPG, JJY, and
RA), in pairs, will independently assess the confidence in
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the estimates (quality of evidence) for each reported out-
come according to the GRADE approach [49]. We will rate
the confidence based on four levels: high, moderate, low,
and very low. For the direct comparisons, we will assess
and rate each outcome based on the following categories:
ROB [50], imprecision [51], inconsistency (which is deter-
mined based on the heterogeneity as described above) [52],
and publication bias [53].
For the assessment of confidence in the estimates, we will
use a recent recommended approach [54]. We will assess
and rate the confidence in all the indirect comparisons—if
available—obtained from first-order loops following the
GRADE categories used for assessing the direct compari-
sons in addition to the transitivity assessment. Transitivity,
also called similarity [55], is the assumption that an indirect
comparison is a valid method to compare two treatments,
because the studies are sufficiently similar in important
clinical and methodological characteristics, or in other
words, that they are similar in their distributions of effect
modifiers [56, 57]. Then, we will rate the confidence in each
NMA effect estimate using the higher rating when both
direct and indirect evidences are present.
We will assess and rate the confidence in estimates of
effect from the direct comparisons in our pair-wise meta-
analyses described previously. For rating confidence in the
indirect comparisons, we will focus our assessments on
first-order loops (FOLs), which are loops connected to the
interventions of interest through only one other interven-
tion. For example, if there are interventions A, B, and C,
and there are direct comparisons, e.g., A vs. B (AB) and B
vs. C (BC), we could indirectly estimate the effects of A vs.
C (AC). The AC indirect estimation will be a FOL. We will
choose the FOL with the lowest variances, and thus con-
tributes the most to the estimates of effect, for rating the
confidence.
Within a FOL, the indirect comparison confidence will be
the lowest of the confidence ratings we have assigned to the
contributing direct comparisons. For example, if we find
that AB has moderate confidence and BC has high confi-
dence, we will judge the associated indirect comparison,
AC, as moderate confidence. We may rate down confidence
in the indirect comparisons further if we have a strong sus-
picion that the transitivity assumption has been violated.
Our overall judgement of confidence in the NMA esti-
mate for any paired comparison will be the highest of the
confidence ratings among the contributing direct and indir-
ect comparisons. However, we may rate down confidence
in the network estimate if we find that the direct and indir-
ect estimates have inconsistency. For this purpose, the
GRADE approach recommends to assess the incoherence
(or inconsistency as described in the “The network meta-
analysis: the direct and the indirect evidence” section) cri-
teria, which is defined as the differences between direct and
indirect estimates of effect [54].
Discussion
Diarrheal diseases remain the major cause for morbidity and
mortality among children. This systematic review will pro-
vide the relative effectiveness of the treatments for AD/
AGE. The results will be of interest for a broad audience: pe-
diatricians, family physicians, general practitioners, guideline
developers, policy makers, and researchers, in both LMIC
and HIC. To the best of our knowledge, our study will be
the first NMA in children to investigate the effectiveness
and safety of all the available standard treatments.
Our planned methods for this review have many
strengths. First, we will implement a wide-search strategy
that included published work in six different databases, as
well as unpublished work. Second, we aim to report im-
portant outcomes in children. Third, our study will take
into account the GDP setting and some other sources of
heterogeneity. Therefore, we will provide effect estimates
that are relevant to most of the clinical settings. On the
other hand, there are some challenges for this review. We
anticipate some degree of clinical heterogeneity with regard
to the possible sources of heterogeneity that we described.
If the extent of included studies is small, the ability to
explore heterogeneity could be limited. Finally, we have
focused only on the analysis of outcomes that are clinically
important and can be studied using NMA in order to pro-
duce important information for decision making, in a
timely and efficient manner.
We hope that this review will provide evidence to reduce
the uncertainty about the ranking of the interventions in
terms of effectiveness and safety, improve child health care,
will find knowledge gaps, and/or will encourage further
research for other therapeutic options.
Glossary of terms
Direct estimate: an estimate provided by a head-to-head
comparison; Indirect estimate: an estimate provided by
two or more head-to-head comparisons that share a com-
mon comparator (e.g., direct comparisons: AB and BC, in-
direct estimation: AC); NMA (network meta-analysis);
combination of direct (when available) and indirect esti-
mates of a comparison; loops: Two or more head-to-head
comparisons that contribute to an indirect estimate. First-
order loops (FOLs) are those loops that involve only a sin-
gle additional intervention; heterogeneity: differences in
estimates of effect across studies that assessed the same
comparison; inconsistency [54]: the GRADE approach cri-
terion for rating the degree of consistency among the re-
sults in the meta-analysis (heterogeneity); incoherence [54]:
the GRADE approach term used as criterion for rating the
inconsistency, specifically in NMA. It refers to the differ-
ences between direct and indirect estimates of effect;
intransitivity[54]: differences in study characteristics that
may modify treatment effect in the direct comparisons, and
could bias the indirect estimate.
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Appendix
Table 2 Example of the search strategy for MEDLINE through Ovid
Ovid MEDLINE(R) in-process and other non-indexed citations, Ovid


















18. exp Bacillus/ or Bacillus.mp.
19. Subtilis.mp.
20. clausii.mp.






































57. exp Zinc Compounds/
























82. (Fermented adj2 milk).tw.
83. delbruecki$.tw.
84. (sour adj1 milk).tw.
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